SNPMiner Trials (Home Page)
Report for Mutation R272G
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 The Effect of Myocilin Genetic Variants on Intraocular Pressure and Blood Pressure Variation in Sitting and Supine Positions.
The purpose of this study is to determine if one of the genes that can cause glaucoma, called myocilin, are associated with larger eye pressure and blood pressure changes in sitting and lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a combination medication called Cosopt® (Merck & Co., Inc.).
NCT00906087 Glaucoma Drug: Cosopt (combination eyedrop of dorzolamide and timolol) MeSH:Glaucoma
HPO:Glaucoma
Effect of Cosopt treatment on blood pressure changes in sitting to supine positions.. Myocilin Mutation Arg272Gly in Subjects. --- Arg272Gly ---
Number of subjects with Myocilin Arg272Gly. --- Arg272Gly ---
Primary Outcomes
Description: Effect of Cosopt treatment on intraocular pressure changes in sitting to supine positions.
Measure: Intraocular Pressure in Sitting and Supine Positions. Time: 10 weeksDescription: Effect of Cosopt treatment on blood pressure changes in sitting to supine positions.
Measure: Blood Pressure in Sitting to Supine Positions Time: 10 weeksSecondary Outcomes
Description: Number of subjects with Myocilin Arg272Gly
Measure: Myocilin Mutation Arg272Gly in Subjects Time: 10 week study